KAY BELL: Open Payments
NPI 1194006312 · PRINCETON, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$840 in 43 payments from 10 companies in 2025. Trend: 2023 $122 · 2024 $136 · 2025 $840
Food & beverage: $840
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $270 |
| Lilly USA, LLC | 12 | $185 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $115 |
| GlaxoSmithKline, LLC. | 4 | $94 |
| Novo Nordisk Inc | 3 | $64 |
| Xeris Pharmaceuticals, Inc. | 1 | $27 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $26 |
| Abbott Laboratories | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $18 |
Products named: MOUNJARO, VRAYLAR, CAPLYTA, UBRELVY, TRELEGY ELLIPTA, Rybelsus, JARDIANCE, GVOKE HYPOPEN.
Industry payments across NC — which companies pay providers there.
